Autolus Therapeutics Reports Third Quarter 2026 Financial Results
Autolus Therapeutics reported third-quarter 2026 financial results, highlighting a 95% year-over-year increase in AUCATZYL net product revenue to $41.2 million.
Stocks · News reference
Autolus Therapeutics announced the online publication of abstracts for the upcoming American Society of Hematology (ASH) Annual Meeting.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Autolus Therapeutics reported third-quarter 2026 financial results, highlighting a 95% year-over-year increase in AUCATZYL net product revenue to $41.2 million.
Autolus Therapeutics (NASDAQ:AUTL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
Filed: 2026-11-10 AccNo: 0001730463-26-000141 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Autolus Therapeutics announced its participation in the upcoming Jefferies Global Healthcare Conference in London.